September 14, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) – Biorem, Inc. (TSX Venture: BRM), a firm that designs and supplies high-efficiency biological-based air emissions control systems, said it has been awarded $1.2 million from the Innovation Demonstration Fund of the Ontario Ministry of Research and Innovation in Canada to support the development of its VOC (volatile organic compound) treatment technology.

The company also said it is installing a prototype VOC treatment system at Polycon Industries (a Magna International division) in Guelph, Ontario. The 5,000 cfm system is scheduled to be operational by fall 2010 and is designed for 95% VOC removal efficiency using biological process developed by Biorem. 

The funding is also aimed at further developing high performance biological systems for low concentration VOC streams, which are present in composting and sewage treatment plants.

Volatile organic compounds are emitted from virtually every manufacturing process. These compounds are contributors to poor air quality in urban areas and contribute to human health issues, such as asthma and certain cancers.

Treatment of VOC emissions has traditionally been through the use of thermal oxidation, a process that uses fossil fuels to remove VOCs by incineration, resulting in significant greenhouse gas emissions and high operating costs.

Canada-based Biorem designs, manufactures and distributes a line of biological-based air emissions control systems. These systems are used to eliminate odors, volatile organic compounds and hazardous air pollutants, and for the conditioning of biogas renewable energy.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html). Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [gvrnmnt] [sstncntss] [biomedphrm] [ntrntnlcmpnsbsnss] [cndnexh] [ndstrls] [mchnrymnfctrng] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.